MEDIA STATEMENT

PHILOGEN ANNOUNCES OPTION AND LICENSE AGREEMENT WITH PFIZER INC. TO DEVELOP AND COMMERCIALIZE MULTIPLE ANTIBODY DRUG CONJUGATES AND TARGETED NANOPARTICLES

Siena, Italy, 22nd December 2014. Philogen S.p.A., a biotechnology company developing antibody and small molecule targeted therapies, today announced that it has entered into an option and license agreement with Pfizer Inc. to develop and commercialise multiple ‘empowered antibodies’.

Philogen brings to the partnership validated antibodies with precise specificity in certain diseases characterised by angiogenesis. “We are very pleased to expand our existing relationship with Pfizer. This new initiative combines Philogen’s validated antibodies with Pfizer’s extensive chemistry and clinical capabilities, and aims to accelerate the potential development of novel Antibody Drug Conjugates (ADCs) into the clinic.” commented Dr. Duccio Neri, Philogen’s CEO. “The industry is seeing mounting interest in ADC technologies, and this agreement with Pfizer underlines the significant potential of these compounds.”

“This agreement with Philogen reflects Pfizer’s commitment to partnerships that advance ADC technology in ways that have the potential to accelerate the delivery of innovative new medicines to cancer patients,” said Robert Abraham, Ph.D., Senior Vice President and Chief Scientific Officer, Oncology Research Unit, Pfizer.

Under the terms of the agreement, Pfizer has exclusive rights to pursue development of certain ADCs and guided nanoparticles. Pfizer will be responsible for research and development and potential commercialization of candidate molecules. In January 2013, Philogen and Pfizer entered into an exclusive license agreement regarding the 'armed antibody' Dekavil, under which Pfizer is exploring the activity of Dekavil for autoimmune diseases.
About Philogen

Philogen is a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products for the treatment of certain diseases that are characterized by angiogenesis.

Philogen’s strategy is to deliver bioactive agents, for example cytokines, radionuclides or drugs to the site of disease using antibodies and ligands that specifically and efficiently target stromal antigens. Philogen helped pioneer this strategy, and has published extensively in leading scientific journals since 1997 in relation to this therapeutic approach. This technology has generated a strong proprietary pipeline of five Phase I/II drugs and also pre-clinical compounds in an array of cancer and chronic inflammatory indications.

Philogen is headquartered in Siena, Italy, where an EMA-certified GMP production facility accelerates transition of its products to the clinic. Philogen also has substantial research activities at its fully-owned subsidiary company Philochem in Zürich, Switzerland. Philogen is independently owned and managed, generates revenue from a diverse range of activities, and has signed agreements with several major pharmaceutical companies.

Philochem has cutting edge platform expertise, including human antibody technology, target discovery programs and DNA-encoded libraries for the isolation of novel chemical entities. In addition, Philogen focuses on exploiting small molecule and antibody drug conjugates.

For more information please visit www.philogen.com